Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
L. Carbognin, S. Pilotto, M. Milella, V. Vaccaro, M. Brunelli, A. Caliò, F. Cuppone, I. Sperduti, D. Giannarelli, M. Chilosi, V. Bronte, A. Scarpa, E. Bria, G. Tortora
PLoS ONE